2024 Annual Report Vistin Pharma ASA

April 25, 2025

Oslo, Norway, 25 April 2025

Please find attached the Annual Report for 2024 for Vistin Pharma ASA (VISTN). There are no material changes in the financial statements compared to the preliminary full year results presented on 13 February 2025.

The annual report for 2024 will also be made available on www.vistin.com.

*****

For further information, please contact:

Alexander Karlsen
CFO
+47 97 05 36 21
[email protected]

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Attachments

Vistinpharmaasa-2024-12-31-0-en
Annual Report 2024 Vistin Pharma ASA

Hot this week

Topics

Popular Categories

News RoomFeatured CompaniesVideos

Middlefield Canadian Income PCC: Net Asset Value(s)

Greenheart Gold Announces Filing of Annual Financial Statements and Provides a Corporate Update

2024 Annual Report Vistin Pharma ASA

Nestlé appoints Jeff Hamilton as CEO Zone Americas, Steve Presley to retire from the company

Transaction in Own Shares

Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor...

Approval of Convertible Loan Note Amendments

Availability of the 2024 Annual Report

Topics

Nestlé appoints Jeff Hamilton as CEO Zone Americas, Steve Presley to retire from the company

Transaction in Own Shares

Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor...

Approval of Convertible Loan Note Amendments

Availability of the 2024 Annual Report

Maisons du Monde : Filing of the 2024 Universal Registration Document

Hubbell Incorporated Declares Regular Quarterly Dividend

Credit Agricole Nord de France – Resultats Financiers au 31 Mars 2025

Related Articles

Nestlé appoints Jeff Hamilton as CEO Zone Americas, Steve Presley to retire from the company

Transaction in Own Shares

Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor...

Approval of Convertible Loan Note Amendments

Availability of the 2024 Annual Report

Company

Headlines

Nestlé appoints Jeff Hamilton as CEO Zone Americas, Steve Presley to retire from the company

Transaction in Own Shares

Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor...

Approval of Convertible Loan Note Amendments

Newsletter